Skyscape Web Viewer : Yao & Artusio's Anesthesiology: Problem-Oriented Patient Management : Medication Index

View All
T3 B.3. Should all or any of the chronic medications be discontinued before the operation? Coagulopathy C.10. What nerve blocks might be beneficial in this patient?
T4 Ambulatory Surgery C.2. How is open repair of thoracic aneurysms performed? C.4. What anesthetic technique would you use for this emergency cesarean delivery? C.7. Which neuromuscular blocking agent would you use? A.7. How are thoracic aortic dissections classified? C.10. When will you extubate the patient's trachea? Describe weight-based extubation criteria. C.2. If you choose epidural anesthesia, describe your technique and dosage. C.7. Could a regional anesthetic technique be used for this surgery? Discuss the advantages and disadvantages of neuraxial anesthesia in this patient for this surgery.
Tacrolimus A.7. What treatments are available for a patient with MG? B.3. How are routine medications and immunosuppressive medications managed in the perioperative period? D.2. What are immunosuppressive agents, and how do they affect anesthetic care? D.6. What immunosuppressive agents will be given after liver transplantation? What are the major side effects? A.7. What are some of the factors that alter insulin requirements? A.9. How are immunosuppressive drugs managed in kidney transplant recipients? D.10. How would you manage this patient in the intensive care unit? D.4. Can renal function change after liver transplantation? E.9. What are the significant implications of drug interactions?
Tapentadol Major and Complex Spine Surgery B.11. What is tramadol? Is it an opioid?
Tensilon A.4. How is the diagnosis of MG made? D.4. How will you define and manage postextubation ventilatory failure in this patient? A.7. What treatments are available for a patient with MG?
Terazosin B.2. How do you pharmacologically prepare the patient with a pheochromocytoma for surgery? B.14. What is the pharmacologic management of CRPS?
Tetanus toxoid
Tetracaine C.2. What is the systemic toxicity of local anesthetics? B.11. What factors determine the onset, potency, and duration of local anesthetic block?
Tetrahydroaminoacridine
Theophylline C.14. What are the effects of anesthetic agents on HPV and their clinical implications? B.14. What medications would you expect the patient to have taken in the past or be taking currently?
Thiopental
Thrombin B.1. What is dabigatran (Pradaxa)? How is its effect measured? How far in advance of elective surgery should it be stopped? Can its effect be reversed? A.10. Why do patients with ESLD have abnormalities of hemostasis? B.4. Discuss the clinical value of assessing standard plasma coagulation testing to predict perioperative bleeding. C.11. What is the role of recombinant activated factor VII (rFVIIa) in the hemorrhaging obstetric patient? C.3. After 3 hours of surgery, the surgeon noticed increased bleeding with oozing from all surgical sites. Blood gas analysis revealed a hemoglobin of 7 g/dL. Describe the pathophysiology of acquired coagulopathy. What are the factors that lead to acquired coagulopathy? C.II-3. How do you monitor heparin dosage? What is the activated coagulation time (ACT) test? D.1. How is myocardial ischemia addressed in the intensive care unit (ICU) following the ASO? B.8. Explain the technical and physiologic principles behind rotational thromboelastometry. C.21. What concentrated factors and hemostatic agents are available for bleeding patients? C.II-1. What anticoagulant would you give before cardiopulmonary bypass (CPB)? How much would you give? What is its mechanism? C.III-3. What are the complications of too much protamine? D.3. Describe the pathophysiology of potential complications following massive transfusion and hematologic resuscitation. What are the risks of thromboembolic complications after intraoperative administration of procoagulants?
Tenormin
Terbutaline
Tetracycline
Thiamine
Thrombolytic Agents
Thyroxine D.2. You have successfully treated the patient's massive hemorrhage. The laboratory values have returned to normal. The patient, however, is still hypotensive despite appropriate intravascular volume replacement and support with vasopressors. What is your concern in this case? A.5. What are the principles of perioperative donor management?
Ticlopidine B.6. What risk is associated with continuing perioperative antiplatelet therapy? What risk is there with stopping it? B.5. What is the conventional recommendation for dual antiplatelet therapy (DAPT) in a patient with previous percutaneous coronary intervention (PCI) undergoing elective noncardiac surgery?
Timolol A.7. Is atropine contraindicated in patients with glaucoma? A.10. Are topically applied ophthalmic medications absorbed systemically? How can this absorption be reduced? Which eye drops can have effects that are of concern to the anesthesiologist?
Tissue plasminogen activator A.10. Why do patients with ESLD have abnormalities of hemostasis? C.6. What physiologic disturbances should be anticipated during the second stage (anhepatic phase) of liver transplantation? D.7. What steps can be taken to prevent cerebral vasospasm? B.4. What types of emergencies can occur during the coiling of an aneurysm, and how should they be managed? D.3. Describe the pathophysiology of potential complications following massive transfusion and hematologic resuscitation. What are the risks of thromboembolic complications after intraoperative administration of procoagulants?
Tobramycin
Topiramate
Tramadol B.11. What is tramadol? Is it an opioid? Cancer Pain Major and Complex Spine Surgery B.5. Would you premedicate this patient? D.2. What is your approach to postoperative pain control?
Tranexamic acid C.10. You decide to use rotational thromboelastometry (ROTEM) to guide your resuscitation efforts. After 20 minutes, the results of the ROTEM are normal; however, the field is still bloody. The surgeon suggests tranexamic acid (TXA) for the patient. What is TXA and what is its mechanism of action? Is TXA effective at reducing blood loss in major spine surgery? What are the risks of TXA administration? Is TXA an appropriate choice in this patient? C.2. Discuss the indications and use of available antifibrinolytic drugs. What dose should be given? Describe the side effects of antifibrinolytic therapy. C.7. When should this patient receive tranexamic acid (TXA)? C.I-17. What antifibrinolytic will you use to reduce blood transfusions? Major and Complex Spine Surgery B.9. What coagulation abnormalities are present after TBI? What modalities can be used to provide hemostasis and reduce intracranial hematoma expansion? C.17. How is hyperfibrinolysis managed? C.21. What concentrated factors and hemostatic agents are available for bleeding patients? C.8. Why does a coagulopathy ensue and how is it prevented/treated? C.II-14. How do you prepare an intravenous (IV) infusion of sodium nitroprusside, nicardipine, and nitroglycerin? What are the usual doses? Which do you prefer to use? Placenta Previa/Placenta Accreta Spectrum
Timoptic
Tizanidine
Tolazoline
Toradol
Triamterene